Mature B-Cell Neoplasms

Viswanatha, David S.; Montgomery, Karen Dyer; Foucar, Kathy

doi:10.1016/b978-0-7216-0040-6.00014-9

Cited by 6 publications

(13 citation statements)

References 293 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 In Table 1, we summarize clinical features of the major reported series on SLL and compare this with the clinical features of a large cohort of CLL patients from M. D. Anderson Cancer Center. 1,4 On peripheral blood smears, CLL and SLL cells are homogenous, small lymphocytes with scanty cytoplasm, round nucleus, inconspicuous nucleoli, and condensed chromatin that impart a ''cracked-mud'' appearance to the nuclei. 5,6,19 Involvement of extranodal sites is common, with the bone marrow (72%) being the most common site.…”

Section: What Is the Clinical And Laboratory Evidence Supporting The mentioning

confidence: 99%

Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia

Santos¹,

O’Brien²

2012

The Cancer Journal

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, characterized by peripheral blood B-cell lymphocytosis as well as lymphadenopathy, organomegaly, cytopenias, and systemic symptoms. Chronic lymphocytic leukemia cells have a distinctive immunophenotype, and the disease has a characteristic pattern of histological infiltration in the lymph node and bone marrow. The clinical course of CLL is heterogeneous, with some patients presenting with very indolent disease and other patients having a more aggressive malignancy. It is known that genetic abnormalities underlie this difference in clinical presentation. Some patients may present solely with lymphadenopathy, organomegaly, and presence of infiltrating monoclonal B cells with the same immunophenotype as CLL cells, but lacking peripheral blood lymphocytosis. This disease is called small lymphocytic lymphoma (SLL) and has been considered for almost 2 decades to be the tissue equivalent of CLL. Both CLL and SLL are currently considered different manifestations of the same entity by the fourth edition of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. It is suspected that differential expression of chemokine receptors (e.g., reduced expression of R1 and CCR3 in SLL cells), integrins (e.g., CLL cells have lower expression of integrin αLβ2), and genetic abnormalities (a higher incidence of trisomy 12 and lower incidence of del(13q) is found in SLL) may explain some of the clinical differences between these 2 disorders. However, there is still a lack of knowledge on the precise biological basis underlying the different clinical presentations of CLL and SLL. It is expected that future studies will shed light on the pathophysiology of both disorders.

show abstract

Section: What Is the Clinical And Laboratory Evidence Supporting The mentioning

confidence: 99%

Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia

Santos¹,

O’Brien²

2012

The Cancer Journal

View full text Add to dashboard Cite

show abstract

“…In the case of CLL/SLL, the restriction of light chain expression is a strong argument for malignancy [2]. The presence of reactive follicles and infiltration with small size lymphocytes raises the differential diagnosis of cutaneous marginal zone lymphoma, which does not express the CD5 and CD23 markers [2,5,8]. FMC7 expression evidenced by flow cytometry raises differential diagnosis problems with MCL, as this is an exception.…”

Section: Histopathological Haematological Laboratory and Imaging Fimentioning

confidence: 99%

“…Lymphoid hyperplasia usually has a nodular, perivascular and periadnexal distribution, with the formation of polarised follicles and a mixed inflammatory infiltrate in the interfollicular area [2,3]. In the case of CLL/SLL, the restriction of light chain expression is a strong argument for malignancy [2]. The presence of reactive follicles and infiltration with small size lymphocytes raises the differential diagnosis of cutaneous marginal zone lymphoma, which does not express the CD5 and CD23 markers [2,5,8].…”

Section: Histopathological Haematological Laboratory and Imaging Fimentioning

confidence: 99%

“…Histopathological differential diagnosis includes several entities: B-cutaneous lymphoid hyperplasia (pseudolymphoma), cutaneous marginal zone B-cell lymphoma, mantle cell lymphoma (MCL), primary cutaneous follicle centre lymphoma (PCF-CL), and skin involvement by follicular lymphoma (FL) [3,5] . Lymphoid hyperplasia usually has a nodular, perivascular and periadnexal distribution, with the formation of polarised follicles and a mixed inflammatory infiltrate in the interfollicular area [2,3]. In the case of CLL/SLL, the restriction of light chain expression is a strong argument for malignancy [2].…”

Section: Histopathological Haematological Laboratory and Imaging Fimentioning

confidence: 99%

“…The disease in its initial stages mostly involves the bone marrow and lymph nodes, with other sites being infrequently affected [2]. Skin infiltration in CLL/SLL is seen in 1-2 % of cases [3].…”

mentioning

confidence: 99%

See 2 more Smart Citations